
# Introduction

- Bictegravir (B; BIC), emtricitabine (F; FTC), and tenofovir alafenamide (TAF; B/F/TAF) is a guidelines-recommended, single-tablet regimen for people living with HIV<sup>1-3</sup>
- B/F/TAF has a high barrier to resistance, favorable drug-drug interaction profile, and ability to be given once daily without food restrictions
- Safety and efficacy through Week 144 have been demonstrated in two Phase 3 studies (GS-US-380-1489 [NCT02607930] and GS-US-380-1490 [NCT02607956]) of B/F/TAF compared with 3-drug dolutegravir (DTG)–containing regimens in treatment-naïve adults<sup>4-8</sup>
- All participants were offered enrollment in an open-label extension (OLE) after completing 144 wk of the randomized portions of the studies

# Objective


To assess 4-y outcomes (Week 48 of the OLE phase/Week 192) from Studies 1489 and 1490

# Methods



# Results


### **Participant Disposition From Baseline to Week 192**



Median age, y (rang Female at birth, n Race/ethnicity, n (% Black or African of

Hispanic/Latinx et Median body weigh Median HIV-1 RNA, HIV-1 RNA >100.0 Median CD4 cells/µl CD4 count <200 ce Asymptomatic H Median eGFR

CD4. cluster of differentiation-4; IQR, interguartile range




- Weeks 144–192

# Virologic Resistance Through Week 192

Participants, Met criteria fo detected **INSTI** resistan detected

any group




# Four-Year Outcomes of B/F/TAF in Treatment-Naïve Adults Kimberly Workowski,<sup>1</sup> Chloe Orkin,<sup>2</sup> Paul Sax,<sup>3</sup> Debbie Hagins,<sup>4</sup> Ellen Koenig,<sup>5</sup> Jeffrey L. Stephens,<sup>6</sup> David A. Wohl,<sup>7</sup> Adriano Lazzarin,<sup>8</sup> Samir K. Gupta,<sup>9</sup> Hailin Huang,<sup>10</sup> Rima Acosta,<sup>10</sup> Jason Hindman,<sup>10</sup> Diana M. Brainard,<sup>10</sup> Sean E. Collins,<sup>10</sup> Hal Martin<sup>10</sup> Baston A Bas

# **Characteristics at B/F/TAF Start**

	Study 1489		Study 1490		
	B/F/TAF n=314	DTG/ABC/3TC to B/F/TAF n=254	B/F/TAF n=320	DTG + F/TAF to B/F/TAF n=265	
nge)	31 (18–71)	36 (22–71)	33 (19–71)	39 (21–80)	
(%)	29 (9)	29 (11)	40 (13)	26 (10)	
%)					
descent	114 (36)	94 (37)	97 (30)	80 (30)	
ethnicity	72 (23)	54 (21)	83 (26)	73 (28)	
ht, kg (IQR)	77 (68, 88)	83 (73, 94)	76 (68, 87)	82 (71, 96)	
A, log <sub>10</sub> copies/mL (IQR)	4.4 (4.0, 4.9)	1.9 (1.5, 3.7)	4.4 (4.0, 4.9)	1.7 (1.4, 3.9)	
00 copies/mL, n (%)	53 (17)	3 (1)	66 (21)	0	
μL (IQR)	443 (299, 590)	766 (599, 1023)	440 (289, 591)	730 (550, 958)	
ells/µL, n (%)	36 (11)	0	44 (14)	3 (1)	
infection, n (%)	286 (91)	229 (90)	286 (89)	234 (88)	
nL/min (IQR)	126 (108, 146)	116 (99, 138)	120 (101, 142)	111 (95, 135)	

#### Virologic Outcomes Through Week 192 on B/F/TAF HIV-1 RNA <50 Copies/mL, Missing = Excluded\*



◆ Efficacy was ≥98% after Week 48 at each study visit through Week 192 in both studies for all participants HIV-1 RNA <50 copies/mL was maintained in participants</li> who switched from DTG-containing regimens to B/F/TAF at

Week 144 to Unblinding			OLE B/F/TAF				
Stud	y 1489	Study 1490		Study 1489		Study 1490	
B/F/TAF n=263	DTG/ ABC/3TC n=269	B/F/TAF n=268	DTG + F/TAF n=281	B/F/TAF n=252	DTG/ ABC/3TC to B/F/TAF n=254	B/F/TAF n=254	DTG + F/TAF to B/F/TAF n=265
0	4†	0	1	0	1	0	1
0	1 (M184V)‡	0	0	0	0	0	0
0	0	0	0	0	0	0	0

eveloped M184V and had assay failure for integrase (IN), INSTL IN strand transfer inhibitor: NRTL nucleoside reverse-transcriptase (RT) inhib

No resistance to any components of B/F/TAF occurred in

		Study 1489	Study 1490
articipants, %		B/F/TAF: n=314	B/F/TAF: n=320
y AE		96	92
	Diarrhea	19	23
	Headache	16	20
	Nasopharyngitis	17	18
	URTI	16	15
	Syphilis	15	14
>10% in either group	Nausea	14	11
	Arthralgia	13	13
	Cough	13	12
	Back pain	13	12
	Fatigue	12	9
	Anxiety	11	6
	Rash	11	5
	Insomnia	11	10
	Influenza	8	11
Any study drug-related AE		32	24
>5% in either group	Headache	5	5
	Diarrhea	6	3
	Nausea	5	3

Participants who switched from DTG/ABC/3TC or DTG + F/TAF


### **Adverse Events Leading to Discontinuation** Through Week 192\*

AEs Leading to D/C		Deaths		
Study 1489: B/F/TAF n=314	Study 1490: B/F/TAF n=320	Study 1489: B/F/TAF n=314	Study 1490: B/F/TAF n=320	
n=1 (<1%)	n=6 (2%)	n=2 (<1%)	n=4 (1%)	
Intervertebral discitis (Day 1366)	Cardiac arrest (Day 28)	Combined toxicity of chloroethane and methamphetamine (Day 771)	Cardiac arrest (Day 28)	
	Paranoia (Day 299)	Self-inflicted wrist wound (Day 656)	Poorly differentiated gastric adenocarcinoma (Day 376)	
	Chest pain (Day 1)		Sudden cardiac arrest (Day 1060)	
	Depression (Day 337)		Hypertensive heart disease (Day 412)	
	Abdominal distension (Day 1)			
	Sleep disorder, dyspepsia, and tension headache (Day 15); depressed mood and insomnia (Day 63)			

I participant (<1%) who switched from DTG/ABC/3TC to</p> B/F/TAF and 1 (<1%) who switched from DTG + F/TAF to B/F/TAF experienced an AE that led to D/C

aboratory Abnormalities Through Week 192*			
Participants, %	Study 1489 B/F/TAF: n=314	Study 1490 B/F/TAF: n=320	
ny Grade 3 or 4 laboratory abnormality	32	29	
:3%			
Increased lipase	20	3	
Increased creatine kinase	11	9	
Increased LDL (fasting)	5	5	
Increased AST	5	3	
Increased ALT	3	3	
Decreased neutrophils	3	3	
Increased amylase	3	3	


#### eGFR Changes From Baseline Through Week 192 on B/F/TAF\*




- No reported cases of proximal renal tubulopathy or D/C due to renal AEs were observed on B/F/TAF
- Changes in eGFR<sub>CG</sub> are consistent with inhibition of tubular creatinine secretion via organic cation transporter-2 by BIC

to B/F/TAF experienced similar AEs as in all B/F/TAF groups


### **Renal Biomarker Changes Through Week 192 on B/F/TAF\***



# 144 of Blinded Phase



#### Weight Changes From Baseline Through Week **192 on B/F/TAF\***



B/F/TAF, kg (IQR): DTG/ABC/3TC to B/F/TAF, +2.4 (-0.3, 4.7); DTG + F/TAF to B/F/TAF, +1.1 (-1.3, 3.9)


# Conclusions


- to B/F/TAF, we observed:
- High rates of virologic suppression with no treatment-emergent resistance
- Few AEs leading to D/C and no renal related D/Cs
- Weight gain of ~3 kg in first 48 wk, followed by approximately 1 kg/year, consistent with data from previous studies in treatment-naïve populations<sup>9-14</sup>
- Small declines in spine and hip BMD from BL, with mean change of  $\leq -1.4\%$  over 4 years of treatment
- These results confirm the long-term safety and efficacy of B/F/TAF

14. Yuh B, et al. Clin Infect Dis 2015:60:1852-9. Acknowledgments: We extend our thanks to the participants, their partners and families, and all GS-US-380-1489 and GS-US-380-1490 investigators. Special thanks to the 1489 and 1490 study teams. These studies were funded by Gilead Sciences. Inc









In treatment-naïve people living with HIV, through 4 years of follow-up among those originally randomized